Long Beach, CA - (NewMediaWire) - February 25, 2019 - Demand Brands, Inc. (OTCPK: DMAN) (“Company” or “DMAN”), a collection of brands and businesses promoting healthy lifestyles, operating in the Health and Wellness, Cannabis Edibles, Hemp and CBD industries http://www.demandbrandsinc.com, announced today that it has launched its Infusional Brand B2B website and will begin offering a limited, initial line of products to wholesale customers http://www.infusional.com .DMAN plans to make the Infusional brand of high quality Hemp and CBD products exclusively available to a network of Physicians, Chiropractors and Pain Management and related clinics. The platform, which the Company intends to more fully build out over the next several months, will allow these professionals to access a premium line of all natural, USA Grown and certified Industrial Hemp products. All Infusional stock will be produced in a certified facility with third party COA analysis.The first Infusional compounds being readied for sale are Hemp derived tinctures, oils and gummy bears formulated using the latest extraction methods with high bioavailability technologies ensuring the highest value absorption rate so patients will receive the maximum benefit of the medicinal properties. The Company’s industrial hemp-derived CBD is non-psychoactive and is more rapidly absorbed in the bloodstream.Current manufacturing techniques now available to cannabinoid producers has significantly improved absorption and solubility rates for nutritional supplements, food and beverages, and other personal care products. Achieving superlative health benefits for consumers is the goal of DMAN and the Company is committed to incorporating the latest advances and innovations into its formulations and supplements.Bruce Hannan, CEO of DMAN, said, “We believe we have a defined and important target market and by offering the Infusional Brand on an exclusive basis it will help set us apart in the marketplace. We plan on developing targeted campaigns as well as focusing on established events and trade show expos to create brand awareness.”About Demand BrandsDemand Brands, Inc. is associated with an array businesses and brands consumers have come to know and trust that market innovative and leading Edibles, Oils, Vapes and Beverage products and manages ventures in the Hemp + Healthy, Cannabis/CBD Superfoods and Education and Technology sectors that promote healthy lifestyles for women, men, children and pets.http://www.demandbrandsinc.comhttps://www.facebook.com/demandbrandshttp://www.twitter.com/demandbrandshttps://www.instagram.com/demandbrands/FDA Disclaimer: Any statements made within this website have not been evaluated by the Food and Drug Administration. No products produced, manufactured, marketed, or distributed are intended to diagnose, treat, cure or prevent any disease. Consult your physician before beginning any supplements or botanical extracts. If pregnant or breast feeding, consult with your physician before use. For use by adults 18+. Keep out of reach of children.This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief", "expects", "intends", "anticipates", “projects” "will", or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.Contact Dale Funk 877-543-4747 info@demandbrandsinc.com
Newport Beach, CA - (NewMediaWire) - February 25, 2019 - ADVANTIS CORPORATION (OTC PINK: ADVT) CEO, Darren Cherry, announced that he plans on signing the lease agreement for the Orange County packaging and distribution location next month. Upon moving in, Cherry hopes to also announce that another one of the company’s existing clients will triple their monthly Amster-Can order.Recent announcements by Cherry continue to point Advantis on a sustained upward trajectory. Earlier this month, Cherry announced plans to open a Los Angeles location in order to double their Amster-Can production overnight. There has been nearly no mention of the Orange County location expansion for the last several weeks, but Cherry says there’s been nothing to announce, as he previously stated that the company was in the final phase of the regulatory process. “We’re ready,” Cherry said. “Our revenue is up, we’re initiating our licensing process, and now we should be ordering two additional pallets a month for one of our existing clients. The additional revenue more than fully supports the expense of the larger and more ideally located space. In fact, the savings of so many other costs associated with our current location will pay for it. The timing is perfect.” Cherry says that he is also excited to move to the new location because it is closer to his home.One of their Orange County clients that has been using other types of canning for its products is currently negotiating to move all of its business to Advantis following the realization of product demand. “I hope to sign the agreement to triple their current pallet-a-month order by next month,” Cherry explained. “I love when our product itself becomes our best marketing strategy. Products packaged in cans have proven to outsell other options time and again. It’s a brilliant marketing solution for our partners and in high demand by the end user. And Now that we package edibles and flower in Amster-Can, our partners are able to send us more of their business almost instantly. We expect this doubling and tripling of orders from our existing clients to be a trend that continues for the foreseeable future.” Cherry concluded his comments by saying the 2018 year-end report will be out shortly, saying, “We are incredibly fortunate for these order increases and are constantly increasing our capacity to keep up with it. The new Orange County location, and how we equip it, will put us ahead of the game for the first time. Last quarter we saw massive order increases, and this quarter we will recognize the lion’s share of that revenue; orders will continue to increase quarter over quarter.”Advantis wishes to thank Investors Hangout for mentioning the company in their podcast. Links to Advantis websites can be found at advantiscorp.com, rosin6.com, elixicure.com, and amstercan.com About Advantis CorporationAdvantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. The company additionally establishes partnerships with businesses that develop and sell proprietary pain management, and consumer products and services. Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward- looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those ...
Las Vegas, NV - (NewMediaWire) - February 25, 2019 - United Rail, Inc. (OTCPK: URAL) , a short line railroad consolidator and owner of the SmartRail brand for electronic Precision Railroading and brand licensor, today announced that it has acquired the New England Southern Railroad, a freight short line railroad, located in Concord, New Hampshire.New England Southern (NES) is a short-line railroad operator and provides a variety of value-added rail transportation services including transloading, private industrial rail car switching and rail car storage. NES leases and operates approximately 22 miles of rail lines in the Concord area.“Our plan is to consolidate the smaller and sometimes overlooked short lines and consolidate them under the United Rail banner,” said Michael Barron, CEO of United Rail.Mr. Barron added, “We plan to aggressively grow our presence in other markets. With the inclusion of the NES under the United Rail umbrella, we now have a presence in the Northeast, an area where we feel there are great growth opportunities.”Danielle M. Mitchell, EVP Business Development for United Rail, stated, “We have been looking for some time to find a partner in this region with the same vision as we have for the consolidation of these small short lines. Now with this deal, we will have a leg up on contacting and closing these rail properties and afford the sellers a path to liquidity.”United Rail will now await final operating authority from the state to begin operations. No financial details of the all cash transaction were disclosed.About United Rail Inc.United Rail, Inc. is in the business of acquiring short line railroads in the freight operations space. The company has been active in this space for several years. It has operated both passenger rail excursions and short line freight operations and plans to develop rail infrastructure projects and terminal operations.Forward-looking StatementsThis press release may contain forward-looking statements regarding United Rail, Inc. (the “Company”) within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements”, including statements regarding: the financial outlook of the Company, the general ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “seeks,” “should,” “could,” “intends,” or “projects” or similar expressions, and involve known and unknown risks and uncertainties. The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, and may be beyond the Company’s ability to foresee or control. The Company does not undertake an obligation to update or revise any forward-looking statements, and all forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.Contact: Michael Mason, EVP United Rail, Inc. michael@unitedrailinc.com 917-841-8371 Media Contact: Success City Online Ms. Maria Bailey Maria@successcityonline.com (702) 271-0591
ANAHEIM, CA - (NewMediaWire) - February 25, 2019 - BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the addition of two new independent directors, Louis Lucido and Luisa Ingargiola, to the Company’s Board of Directors.“We are delighted to welcome Lou and Luisa as new independent directors. Luisa has served as both a CFO and board member of multiple public companies, and has been instrumental in assisting several of these companies in the uplisting process to a senior national exchange. Lou brings extensive business acumen, having founded and helped run a multi-billion dollar asset management firm. As we continue executing on our growth strategy and plan for a Nasdaq listing, these new directors bring a wide range of relevant experience. We believe that the breadth, depth and diversity of their experience in both corporate finance and capital markets will strengthen BioCorRx on many levels,” said Brady Granier, CEO, President and Director of BioCorRx. “They have impressive track records and we look forward to working with them as we believe they will have a meaningful impact on BioCorRx’s future growth.”Louis LucidoLouis Lucido was formerly the Senior Advisor and Chief Operating Officer of DoubleLine Group, LP, a large investment firm with over $100 billion in assets under management. He recently retired in December 2018 and was one of the five founding partners. He was previously at TCW, where he served as a Group Managing Director. Prior to joining TCW in 2001, Mr. Lucido was the Chief Investment Officer for Delphi Financial Group (DFG) and was on several subsidiary boards. Before DFG, he was the Chief Operating Officer and Secretary for Hyperion Capital Management and was also a member of the Resolution Trust Advisory Committee. Since February 2013, he has served as a member of the Board of Directors of CASA of Los Angeles and is the current Chairman. Additionally, he was elected in 2013 and currently serves on the Boards of Junior Achievement, Southern California ,826LA and the Lupus Research Alliance (formerly the Alliance for Lupus Research). Mr. Lucido received his MBA in Management and Finance from New York University, and was a member of the Dean’s Advisory Board of the N.Y.U. Stern School of Business.Luisa IngargiolaLuisa Ingargiola presently serves as Chief Financial Officer of Avalon GloboCare, a leading global developer of cell-based technologies and therapeutics, where she helped navigate its Nasdaq uplisting in 2018. Luisa is a Board Director and Audit Chair of Electra Meccanica, a Nasdaq-listed company designing and manufacturing electric vehicles; she also serves on the board of Globe Photos, a leader in licensed sports photographic prints and iconic pop culture imagery; and she serves as director of Operation Transition Corporation, a strategic consulting and advisory firm that places ex-military special operations forces into corporate careers. Luisa holds a Bachelor of Science in Finance from Boston University, and an MBA in Health from the University of South Florida.About BioCorRxBioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more ...
MAKATI, Philippines - (NewMediaWire) - February 25, 2019 - Before 2019 Mobile World Congress, Smart Communications announced that they are building the 5G oriented DIS (Digital Indoor System) in Smart Tower, to provide ubiquitous high-quality user experience while supporting smooth evolution to 5G. This is a significant step to embrace the arrival of upcoming 5G era.Smart Tower is a 36-story skyscraper in the heart of Makati CBD and is the headquarters of Smart Communications. Currently the indoor networks are supported by DAS which provides 2G, 3G and LTE services. SMART Tower houses thousands of Smart employees and are in constant need of data services to fulfill both their professional and personal needs throughout the day. With a highly tech savvy workforce, a Digital Indoor System provide the best network in capacity and user experience. As SMART Tower also houses the Innovation Lab focusing on next generation technology and use cases such as 5G, the DIS will ensure that when needed, the DIS will smoothly evolve to support 5G network supporting eMBB, uRLLC and eMTC use cases.The existing DAS networks have been strained to satisfy these service requirements. For example, DAS does not support smooth capacity expansion as reconstructions are required to introduce multi-antenna solutions, which is a key component to 5G. DAS also requires tremendous O&M efforts and takes a long time to construct, making it unsuitable to meet the requirements of fast deployment.As one of Huawei's DIS-based solutions, LampSite Pro is easy to deploy. It provides huge capacity, supports multi-mode multi-band applications, and E2E visualized O&M. These features give it unique strengths to tangibly improve coverage and eliminate blind holes in the offices scenario, helping provide ubiquitous MBB experience to end-users. Data obtained from a DIS deployment in one of the major entertainment arena demonstrated significant uplink and downlink traffic increment by 100+%, indicating an efficient release of long-suppressed traffic. The downlink rate at the user end was constant even with the increase of user traffic, with peak data rate of 300+Mbps recorded, showing a significantly improved user experience. Additionally, this digital indoor system has the capability to evolve into future-oriented 5G networks without the need for additional cabling.Joachim Horn, Chief Technology and Information Advisor of PLDT and Smart, said: “Boosting our indoor coverage is part of the broader network improvement program of PLDT and Smart, which is focused on creating the best customer experience especially for data. Improving indoor coverage is important because people use their data heavily while inside buildings.”John Leung John.leung@wmglobal.com
Barcelona, SPAIN - (NewMediaWire) - February 25, 2019 - At the eve of 2019 Mobile World Congress, South Korean carrier LG Uplus and Huawei jointly announced the establishment of the Gbps 5G commercial network. The two sides have completed the deployment of more than 10,000 sites. LG Uplus and Huawei also cooperate to demonstrate the ultra-HD video and VR services based on 5G networks and enable new 5G commercial applications.At the LG booth in MWC2019, LG Uplus and Huawei will jointly demonstrate 5G network services. As an important application of eMBB, VR will become a mainstream service in the 5G era and has been widely recognized by global carriers. Cloud VR will become a killer application. On January 22, 2019, LG Uplus showcased the world's first 5G Cloud VR-based game. It fully leveraged the capabilities of 5G broad bandwidth and low latency, and won high praise from onsite media and customers.Huawei's 5G products are mature in commercial use and have been widely recognized in the industry. They support large-scale 5G commercial deployment in the world. On February 25, 2019, Huawei will release a full-scenario 5G commercial system to provide a simplified 5G solution, including network simplification, simplified architecture, simplified site, low power consumption, and simplified O&M. Huawei helps customers reduce deployment costs, support fast commercial deployment, and build the best 5G network. In Seoul, South Korea, LG Uplus collaborated with Huawei to deploy 5G base stations over 10,000 sites. Huawei 5G AAU is deployed on the network to provide continuous coverage of 5G network. The average data rate of Golden Cluster in Gangnam District exceeds 900Mbps, which provides customers with stable and high-performance. This also demonstrates the excellent performance of Huawei's 5G products.LG Uplus in South Korea and Huawei have been firmly engaged in 5G cooperation, jointly promoting the 5G commercialization process, and dedicated to providing the best mobile service experience for users.MWC 2019 will be held from February 25 to February 28 in Barcelona, Spain. Huawei will showcase its products and solutions at booth 1H50 in Fira Gran Via Hall 1, booth 3I30 in Hall 3, the Innovation City zone in Hall 4, booth 7C21 and 7C31 in Hall 7. For more information, please visit http://carrier.huawei.com/en/events/mwc2019John Leung John.leung@wmglobal.com
Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development Irvine, CA - (NewMediaWire) - February 25, 2019 - Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD). CBIS and its research collaborator are currently investigating the potential beneficial effects of cannabidiol on oro-bucco-lingual dyskinesias, oxidative stress, and psychosis using animal studies and a clinical trial. CBIS recently announced receipt of U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders, and PTSD, among other target indications.The invention relates to a composition for use in the treatment of neurobehavioral disorders utilizing various Cannabis plant extracts comprising CBN preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from Cannabis Sativa and/or Cannabis Indica and/or Cannabis ruderalis and/or other elements, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against Sleeping Disorders, in particular Insomnia, PTSD, and anxiety disorders including Attention Deficit Hyperactivity Disorder (ADHD).The animal studies are well underway and should be completed in the coming months. This study is important in a country like Nigeria where movement disorders are still common because the relatively inexpensive conventional antipsychotics are still widely in use. Movement disorders are known to be more common in patients on the conventional antipsychotics, though they have also been reported in the atypical antipsychotics. It is therefore pertinent to continue to search for new and better forms of management of this difficult to manage movement disorder in psychotic patients. CBIS has entered into an initial, one-year Research Collaboration Agreement with Stellenbosch University. CBIS and Stellenbosch University intend to jointly develop and investigate the use of Cannabinoids to treat chronic pelvic pain disorder/chronic prostatitis, and potentially other indications. Stellenbosch University (SU) is one of the oldest Universities in South Africa. The research is being conducted in South Africa and Nigeria.Cannabis Science is aggressively expanding the Company’s network of research centers. Negotiations are ongoing with several academic institutions in the United States and internationally to establish new, collaborative research agreements. These contracts will focus on several indications, and are expected to expand the research funded, and directed by the Company. In addition, Cannabis Science will develop multi-center, clinical trial networks with cannabinoid drug development.“We are encouraged with the preliminary results from our pre-clinical work and animal studies in Nigeria,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “The research may be of use in other movement disorders, such as Huntington’s Disease, Tourette’s Syndrome, Cerebral Palsy, and Dystonia. These could be related through the neurotransmitter, dopamine, modulated by the CB1 receptors. While we will continue our research in regard to oro-bucco-lingual dyskinesias, oxidative stress, and psychosis, we believe there is an opportunity to expand our research in Nigeria to include PTSD. Specifically, we will develop a protocol for a PTSD clinical study immediately and begin this study as soon as possible. This will allow the Company to leverage our patent for compositions of cannabinol (CBN), as well as our expertise with other cannabinoids.”“Our work in Nigeria, while independent of our research collaborations in the U.S., contributes significantly to the Global Consortium we launched last year,” added Mr. Dabney. The Cannabis ...
Seattle, WA - (NewMediaWire) - February 25, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Aleafia Health Inc. (TSX-V: ALEF) (OTCQX: ALEAF) (FRA: ARAH). The vertically-integrated licensed producer with a clinic network and over 50,000 patients, was named as the 2019 TSX Venture 50 top performing company of the year. The TMX Group’s annual performance awards are based on three equally weight criteria, including market capitalization growth, share price appreciation and trading volume.The TSX Venture exchange has become a popular place for cannabis companies to list their shares, particularly after Canada legalized recreational cannabis last year, but 2019 was the first year that a cannabis company topped its annual performance rankings.The award demonstrates the company’s increasing popularity in the space. Over the past 52 weeks, the company’s stock price rose from a low of $0.47 to a high of $4.70 before settling at its current levels of around $2.37, making it a popular stock for active traders interested in the cannabis industry. As such, daily trading volume averaged roughly 1.42 million shares over the past three months, providing significant liquidity for investors.Research Proves a Strong CatalystAleafia Health’s stock reached all-time highs back in late-September when it partnered with Cronos Group Inc. to study the effects of medical cannabis on insomnia and daytime sleepiness. Under the terms of the deal, Cronos Group would provide funding for the study, which would be conducted by doctors at Aleafia’s health clinics. The company also formally launched Aleafia Labs to focus on these research projects.The company’s stock also moved sharply higher when it announced positive results from its benzodiazepine study. After conducting a study with 146 patients, the company reported that 45.2 percent of patients stopped consuming benzodiazepines—as a sedative or anti-anxiety medication—following a medical cannabis prescription. The patients further reported decreased daily distress due to their medical condition.These research projects leverage the company’s wholly-owned network of more than 20 Canabo Medical Clinics with over 50,000 patients. With the largest medical cannabis dataset in the world, the company enables researchers to validate cannabis science, product teams to innovate, and management to build a strong portfolio of intellectual property. The division had already generated $612,000 in revenue by the third quarter of 2018.Appealing to Both Traders & InvestorsMany cannabis stocks appeal to active traders that look for important catalysts and price movements, but only a fraction of these companies are also attractive on a fundamental basis to long-term investors. Aleafia Health is an existing licensed producer with an experienced management team, 98,000 kilograms per year of production capacity expected this year, and a network of medical cannabis clinics with over 50,000 patients.The company already generates tangible revenue from its medical cannabis clinics, research activities and supply agreement with CannTrust Holdings Inc.. After merging with Emblem Corp., the company has amassed a significant production footprint that it’s expanding further through strategic investments around the world. At the same time, its massive cannabis dataset provides an invaluable competitive advantage.Currently, the company trades with a market capitalization of about $375 million, which is lower than many other licensed producers. As the company scales up production and research activity, investors may become increasingly interested in the growing revenue and cash flow. The R&D activity could also pave the way towards valuable revenue streams from licensing, which may help boost revenue and margins over the long-term.Click Here to Download Aleafia Health Inc.’s Investor PresentationLooking AheadAleafia Health Inc. (TSX-V: ALEF) (OTCQX: ALEAF) (FRA: ARAH) represents a compelling ...
Statement Highlights: New developments in identifying and treating the increased risk of premature heart disease in children and teens with certain medical conditions associated with increased cardiovascular risk are discussed in a scientific statement from the American Heart Association. Obesity and severe obesity are now considered significant risk factors for an increased risk of cardiovascular disease in children and teens. Embargoed until 4 a.m. CT / 5 a.m. ET Mon. Feb. 25, 2019 (NewMediaWire) - February 25, 2019 - DALLAS - Obesity and severe obesity in childhood and adolescence have been added to the list of conditions that put children and teens at increased risk for premature heart disease, according to a new scientific statement from the American Heart Association published in the Association’s journal Circulation. The statement provides an overview of current scientific knowledge about managing and treating the increased risk of atherosclerosis and early heart disease, in children and teens with type 1 or 2 diabetes, familial high cholesterol, congenital heart disease, childhood cancer survivorship and other conditions. Atherosclerosis is the slow narrowing of the arteries that underlies most heart diseases and stroke. “Parents need to know that some medical conditions raise the chances of premature heart disease, but we are learning more every day about how lifestyle changes and medical therapies that can lower their cardiovascular risk and help these children live their healthiest lives,” said Sarah de Ferranti, M.D., M.P.H., chair of the writing group for the statement and chief of the Division of Cardiology Outpatient Services at the Boston Children’s Hospital in Massachusetts. For example, there are treatments for familial high cholesterol – a group of genetic disorders that affect how people process cholesterol which can lead to extremely high cholesterol levels – that can help children and teens with this disorder live a normal lifespan. The statement is an update of a 2006 scientific statement and adds obesity and severe obesity to the list of conditions that put children and teens at increased risk of cardiovascular diseases and reviews new treatments for previously discussed conditions. Severe obesity and obesity are now considered moderate risk and at-risk conditions respectively because research shows they significantly increase chances of developing heart disease later in life. A study of almost 2.3 million individuals followed for over 40 years found the risks of dying from a cardiovascular disease were two to three times higher if their body weight as adolescents had been in the overweight or obese category compared to youth with normal weight. Effective treatments for obesity have proven elusive, but in general, a gradual approach to weight loss is generally required, incorporating improvements in dietary quality, fewer calories, more physical activity, meal replacements, medical therapy and/or bariatric surgery depending on the severity of the excess adiposity. Other significant changes to the statement since 2006 include: The elevation of Type 2 diabetes to a high-risk condition because of its association with additional cardiovascular risk factors such as high blood pressure and obesity. The expansion of the risks of premature heart disease associated with treatments for childhood cancers. Co-authors are Julia Steinberger, M.D., M.S.(Co-Chair); Rebecca Ameduri, M.D.; Annette Baker, R.N., M.S.N., C.P.N.P.; Holly Gooding, M.D., M.Sc.; Aaron S. Kelly, Ph.D.; Michele Mietus-Snyder, M.D.; Mark M. Mitsnefes, M.D., M.S.; Amy L. Peterson, M.D.; Julie St-Pierre, M.D., Ph.D.; Elaine M. Urbina, M.D., M.S.; Justin P. Zachariah, M.D., M.P.H.; and Ali N. Zaidi, M.D. Author disclosures are on the manuscript. Additional Resources: After Feb. 25, view the manuscript online. Obesity as young adult sets stage for heart disease, stroke Podcast - Children and Familial Hypercholesterolemia Age at cancer diagnosis may affect the risk of death from heart disease Follow AHA/ASA news on Twitter @HeartNews ### The ...
